Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035428 | 0.78 | PTPN2 (0.53) | PLAU | |
| SCHEMBL31098661 | 0.76 | HTR6 (0.60) | HTR6ALDH1A1ULK1 | |
| SCHEMBL8888959 | 0.76 | PARP1 (0.55) | ADORA1ADORA2AADORA3PARP1ALDH1A1 | |
| SCHEMBL12753130 | 0.75 | ALDH1A1 (0.51) | ADORA1ADORA2AADORA3ALDH1A1 | |
| SCHEMBL28411602 | 0.74 | P2RX7 (0.52) | PARP1ALDH1A1 | |
| SCHEMBL17772324 | 0.74 | PARP1 (0.43) | PLAUPIM1PIM2GSK3AGSK3B | |
| SCHEMBL18380148 | 0.73 | GSK3A (0.52) | PIM2ADORA1ADORA2AADORA3GSK3A | |
| SCHEMBL17772337 | 0.72 | KDR (0.53) | ADORA1ADORA3PARP1ALDH1A1 | |
| SCHEMBL31367875 | 0.72 | SIRT2 (0.59) | ALDH1A1 | |
| SCHEMBL2557090 | 0.71 | KDM4E (0.63) | ADORA3PARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2273992-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | PLAU 4007/4885PIM1 4218/4885PIM3 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.